Catalyst Brief

← Calendar

Readoutin 14d

TransThera Sciences (Nanjing), Inc. — Tinengotinib 8 mg

Phase 3 primary completion: Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma.

Date
Dec 2026
Type
Readout
Indication
Cholangiocarcinoma

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.